{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:20:04Z","timestamp":1787732404003,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6\\u20132022-0174"],"award-info":[{"award-number":["6\\u20132022-0174"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2023\\u201300279682"],"award-info":[{"award-number":["RS-2023\\u201300279682"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctro.2025.101069","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T07:10:16Z","timestamp":1763277016000},"page":"101069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Consolidation ICIs Alter cardiac subregion radiosensitivity in NSCLC patients treated with Chemo-Radiotherapy"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-1502","authenticated-orcid":false,"given":"Yejin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeon","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joongyo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Geol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9966-5157","authenticated-orcid":false,"given":"Jaeho","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2106-6856","authenticated-orcid":false,"given":"Hong In","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-4489","authenticated-orcid":false,"given":"Clemens","family":"Grassberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ctro.2025.101069_b0005","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1158\/1078-0432.CCR-10-2760","article-title":"New strategies in Non\u2013Small Cell Lung Cancer: improving Outcomes in Chemoradiotherapy for locally Advanced Disease","volume":"17","author":"Rengan","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ctro.2025.101069_b0010","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2025.101069_b0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2019.05.027","article-title":"Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer","volume":"134","author":"Melosky","year":"2019","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ctro.2025.101069_b0020","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/1759-7714.13631","article-title":"Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of asian ethnicity with unresectable stage III non\u2010small cell lung cancer: chinese multicenter report and literature review","volume":"11","author":"Zhang","year":"2020","journal-title":"Thorac Cancer"},{"issue":"13","key":"10.1016\/j.ctro.2025.101069_b0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac Toxicity after Radiotherapy for Stage III Non\u2013Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2025.101069_b0030","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jamaoncol.2022.4202","article-title":"Association of Sinoatrial Node Radiation Dose with Atrial Fibrillation and Mortality in patients with Lung Cancer","volume":"8","author":"Kim","year":"2022","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.ctro.2025.101069_b0035","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","article-title":"Cardiac events after Radiation Therapy: combined Analysis of prospective Multicenter Trials for locally Advanced Non\u2013Small-Cell Lung Cancer","volume":"35","author":"Dess","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2025.101069_b0040","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ijrobp.2022.11.033","article-title":"Left Anterior Descending Coronary Artery Radiation Dose Association with All-Cause Mortality in NRG Oncology Trial RTOG 0617","volume":"115","author":"McKenzie","year":"2023","journal-title":"Int J Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2025.101069_b0045","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-Term results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy with or without Cetuximab for Unresectable Stage III Non\u2013Small-Cell Lung Cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2025.101069_b0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jtho.2023.01.085","article-title":"Demystifying the results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated with overall Survival","volume":"18","author":"McWilliam","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2025.101069_b0055","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jtho.2018.05.028","article-title":"Dosimetric Predictors of Symptomatic Cardiac events after Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC","volume":"13","author":"Yegya-Raman","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2025.101069_b0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamaoncol.2020.6332","article-title":"Association of Left Anterior Descending Coronary Artery Radiation Dose with Major Adverse Cardiac Events and Mortality in patients with Non\u2013Small Cell Lung Cancer","volume":"7","author":"Atkins","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2025.101069_b0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.radonc.2020.09.050","article-title":"Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer","volume":"152","author":"Jang","year":"2020","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2025.101069_b0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","article-title":"Cardiac Toxicity of Thoracic Radiotherapy: existing evidence and Future Directions","volume":"16","author":"Banfill","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2025.101069_b0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaccao.2020.07.005","article-title":"Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer patients from a Rural setting","volume":"2","author":"Moey","year":"2020","journal-title":"JACC CardioOncology"},{"issue":"9","key":"10.1016\/j.ctro.2025.101069_b0080","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2025.101069_b0085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaccao.2022.06.008","article-title":"What is the evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor\u2013Induced Myocarditis?","volume":"4","author":"Thuny","year":"2022","journal-title":"JACC CardioOncology"},{"issue":"6","key":"10.1016\/j.ctro.2025.101069_b0090","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC CardioOncology"},{"issue":"7","key":"10.1016\/j.ctro.2025.101069_b0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients Treated with Anti\u2013Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2025.101069_b0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global Longitudinal Strain and Cardiac events in patients with Immune Checkpoint Inhibitor-Related Myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ctro.2025.101069_b0105","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxicities: a review","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.ctro.2025.101069_b0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctro.2025.101069_b0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation\u2010Induced Cardiovascular Disease: Review of an Underrecognized Pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ctro.2025.101069_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110477","article-title":"Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing","volume":"200","author":"Huang","year":"2024","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2025.101069_b0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaccao.2024.05.009","article-title":"Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer","volume":"6","author":"Walls","year":"2024","journal-title":"JACC CardioOncology"},{"issue":"4","key":"10.1016\/j.ctro.2025.101069_b0130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaccao.2024.07.005","article-title":"Cardiac Substructure Radiation Dose and Associations with Tachyarrhythmia and Bradyarrhythmia after Lung Cancer Radiotherapy","volume":"6","author":"Atkins","year":"2024","journal-title":"JACC CardioOncology"},{"issue":"6","key":"10.1016\/j.ctro.2025.101069_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctro.2025.101069_b0140","doi-asserted-by":"crossref","unstructured":"Kakiuchi Y, Saruwatari K, Murotani K, et al. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study. Clin Lung Cancer. Published online July 2024:S1525730424001396. doi:10.1016\/j.cllc.2024.07.001.","DOI":"10.1016\/j.cllc.2024.07.001"},{"key":"10.1016\/j.ctro.2025.101069_b0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2020.09.045","article-title":"Clinical evaluation of atlas- and deep learning-based automatic segmentation of multiple organs and clinical target volumes for breast cancer","volume":"153","author":"Choi","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2025.101069_b0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and Validation of a Heart Atlas to Study Cardiac Exposure to Radiation following Treatment for Breast Cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2025.101069_b0155","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/j.prro.2021.02.002","article-title":"A Radiation Therapy Contouring Atlas for Cardiac Conduction Node Delineation","volume":"11","author":"Loap","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2025.101069_b0160","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3348\/kjr.2021.0148","article-title":"Fully Automatic Coronary Calcium score Software Empowered by Artificial Intelligence Technology: Validation Study using three CT Cohorts","volume":"22","author":"Lee","year":"2021","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.ctro.2025.101069_b0165","unstructured":"Brock G, Barnes C, Ramirez J, Myers J. R code for calculating the competing risks estimates."},{"issue":"1","key":"10.1016\/j.ctro.2025.101069_b0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jtho.2022.09.004","article-title":"Cardiac Function Modifies the Impact of Heart Base Dose on Survival: a Voxel-Wise Analysis of patients with Lung Cancer from the PET-Plan Trial","volume":"18","author":"Craddock","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2025.101069_b0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.07.053","article-title":"Radiation dose to heart base linked with poorer survival in lung cancer patients","volume":"85","author":"McWilliam","year":"2017","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctro.2025.101069_b0180","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-023-00986-9","article-title":"Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure","volume":"21","author":"Gergely","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"29","key":"10.1016\/j.ctro.2025.101069_b0185","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of Cardiovascular events in patients Treated with Immune Checkpoint Inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2025.101069_b0190","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ijrobp.2021.03.005","article-title":"Mean Heart Dose is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the risk of Major adverse Cardiac events in Lung Cancer Radiation Therapy","volume":"110","author":"Atkins","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2025.101069_b0195","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ijrobp.2020.02.017","article-title":"Should we move beyond mean Heart Dose?","volume":"107","author":"Loap","year":"2020","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2025.101069_b0200","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijrobp.2022.05.011","article-title":"Beyond mean Heart Dose: Cardiac Metrics for the Modern Era","volume":"114","author":"Jimenez","year":"2022","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2025.101069_b0205","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","article-title":"Late Cardiac Toxicity after Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and whole Heart Dose-volume Variables to Risk Prediction","volume":"98","author":"Hahn","year":"2017","journal-title":"Int J Radiat Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2025.101069_b0210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamaoncol.2020.7468","article-title":"Association of Breast Cancer Irradiation with Cardiac Toxic Effects: a Narrative Review","volume":"7","author":"Meattini","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2025.101069_b0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13014-020-01520-8","article-title":"Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks","volume":"15","author":"Gaasch","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101069_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110005","article-title":"Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation","volume":"190","author":"Yegya-Raman","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:34:31Z","timestamp":1787729671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630825001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"alternative-id":["S2405630825001612"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101069","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidation ICIs Alter cardiac subregion radiosensitivity in NSCLC patients treated with Chemo-Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101069"}}